Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W H Kruit

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
The Netherlands Journal of Medicine|August 1, 1991
Riedel's thyroiditis in a patient with retroperitoneal fibrosisW H Kruit, G J den Ottolander
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Interferon-alpha induced Raynaud's syndromeW H Kruit, A M Eggermont, G Stoter
Cancer Immunology, Immunotherapy : CII|September 4, 1999
The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cellsW H Kruit, P I Schmitz, G Stoter
Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fur Klinische Chemie Und Klinische Biochemie|January 1, 1984
Haptoglobin typing, is it clinically necessary for a reliable determination of haptoglobin with the single radial immunodiffusion technique?H J van Rijn, W H Kruit, J Schrijver
Nederlands Tijdschrift Voor Geneeskunde|August 12, 1999
[Side effects of interferon alfa]L Berk, A R van Gool, M Bannink, et al.
Journal of Internal Medicine|October 1, 1991
The significance of venography in the management of patients with clinically suspected pulmonary embolismW H Kruit, A C de Boer, A K Sing, et al.
European Journal of Clinical Investigation|April 12, 2000
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein responseT C Stam, A J Swaak, W H Kruit, et al.
British Journal of Cancer|November 21, 1998
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patientsR de Wit, W H Kruit, G Stoter, et al.
Acta Neuropsychiatrica|March 16, 2016
Management of psychiatric adverse events with immunotherapy with interferon-alfaA R Van Gool, W H Kruit, J J Cornelissen, et al.
Journal of the National Cancer Institute|October 2, 1996
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportR de Wit, J Verweij, M Bontenbal, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
The Netherlands Journal of Medicine|August 1, 1991
Riedel's thyroiditis in a patient with retroperitoneal fibrosisW H Kruit, G J den Ottolander
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Interferon-alpha induced Raynaud's syndromeW H Kruit, A M Eggermont, G Stoter
Cancer Immunology, Immunotherapy : CII|September 4, 1999
The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cellsW H Kruit, P I Schmitz, G Stoter
Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift Fur Klinische Chemie Und Klinische Biochemie|January 1, 1984
Haptoglobin typing, is it clinically necessary for a reliable determination of haptoglobin with the single radial immunodiffusion technique?H J van Rijn, W H Kruit, J Schrijver
Nederlands Tijdschrift Voor Geneeskunde|August 12, 1999
[Side effects of interferon alfa]L Berk, A R van Gool, M Bannink, et al.
Journal of Internal Medicine|October 1, 1991
The significance of venography in the management of patients with clinically suspected pulmonary embolismW H Kruit, A C de Boer, A K Sing, et al.
European Journal of Clinical Investigation|April 12, 2000
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein responseT C Stam, A J Swaak, W H Kruit, et al.
British Journal of Cancer|November 21, 1998
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patientsR de Wit, W H Kruit, G Stoter, et al.
Acta Neuropsychiatrica|March 16, 2016
Management of psychiatric adverse events with immunotherapy with interferon-alfaA R Van Gool, W H Kruit, J J Cornelissen, et al.
Journal of the National Cancer Institute|October 2, 1996
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportR de Wit, J Verweij, M Bontenbal, et al.
Pageof 3